Teoxane SA
17
2
5
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
12%
2 trials in Phase 3/4
90%
9 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows
Role: lead
TCRM for Correction of Cheek Including Fine Lines
Role: lead
Safety and Effectiveness Evaluation of TEOSYAL® TPVM Versus COMPARATOR for the Remodeling of the Lower Face
Role: lead
RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)
Role: lead
RHA®4 for Midface Volume Deficiency
Role: lead
RHA® 3 Versus Restylane-L® for Lip Augmentation
Role: lead
TEOSYAL RHA® 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese Adults
Role: lead
TEOSYAL® PureSense ULTRA DEEP Versus Restylane® Lidocaine for the Correction of Moderate to Severe Nasolabial Folds in Chinese Adults
Role: lead
RHA Redensity - Perioral Rhytids
Role: lead
RHA® 4 NLF Cannula
Role: lead
TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines
Role: lead
RHA® Redensity With New Anesthetic Agent - Perioral Rhytids
Role: lead
RHA® 4 With New Anesthetic - Nasolabial Folds
Role: lead
TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds
Role: lead
TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds
Role: lead
Efficacy and Safety of a Commercially Available Injectable Hyaluronic Acid Dental Filler for Periodontal Pockets
Role: lead
TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles
Role: lead
All 17 trials loaded